Creative Medical Technology Holdings, Inc. (CELZ) shareholders
CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.53−0.09 (-14.35%)
Close on Nov 13, 2026Market cap $3.48MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5.7%
0M of 7M shares
Institutional holders
13
5 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Timothy Warbington Joint filing with Creative Acquisition Corp. (13.20%) | 1,040,762 | 13.70% | 13D (active) | Sep 24, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CELZ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hudson Bay Capital Management LP | 135,170 | 2.05% | $196.00K | New | 0.00% |
| Anson Funds Management LP | 105,549 | 1.60% | $153.05K | New | 0.01% |
| Armistice Capital, LLC | 42,000 | 0.64% | $60.90K | New | 0.00% |
| XTX Topco Ltd | 26,559 | 0.40% | $38.51K | +12,299 | 0.00% |
| Geode Capital Management, LLC | 25,799 | 0.39% | $37.42K | −12,491 | 0.00% |
| Vanguard Capital Management LLC | 20,350 | 0.31% | $29.51K | – | 0.00% |
| Vanguard Fiduciary Trust Co | 5,518 | 0.08% | $8.00K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 4,853 | 0.07% | $7.04K | +2,761 | 0.00% |
| Global Retirement Partners, LLC | 4,118 | 0.06% | $5.97K | New | 0.00% |
| UBS Group AG | 2,061 | 0.03% | $2.99K | +2,060 | 0.00% |
| Morgan Stanley | 514 | 0.01% | $745 | −20 | 0.00% |
| Barclays PLC | 54 | 0.00% | $78 | New | 0.00% |
| SBI Securities Co., Ltd. | 43 | 0.00% | $62 | +42 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 0M | 5.7% | 5 / 4 | 2 / 3 | 0M | 0M |
| Q1 2026 | 11 | 0M | 1.5% | 6 / 2 | 2 / 6 | 0M | 0M |
| Q4 2025 | 14 | 0M | 2.0% | 5 / 3 | 1 / 3 | 0M | 0M |
| Q3 2025 | 12 | 0M | 1.1% | 4 / 3 | 1 / 4 | 0M | 0M |
| Q2 2025 | 12 | 0M | 1.1% | 4 / 2 | 2 / 3 | 0M | 0M |
| Q1 2025 | 11 | 0M | 3.1% | 3 / 4 | 0 / 0 | 0M | 0M |
| Q4 2024 | 8 | 0M | 0.5% | 1 / 2 | 2 / 3 | 0M | 0M |
| Q3 2024 | 10 | 0M | 1.0% | 1 / 1 | 3 / 0 | 0M | 0M |
| Q2 2024 | 9 | 0M | 1.1% | 1 / 5 | 3 / 5 | 0M | 0M |
| Q1 2024 | 13 | 0M | 1.6% | 7 / 4 | 0 / 2 | 0M | 0M |
| Q4 2023 | 8 | 0M | 0.3% | 1 / 1 | 4 / 1 | 0M | 0M |
| Q3 2023 | 8 | 0M | 0.3% | 0 / 3 | 2 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held CELZ in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CELZ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 27,549 | 0.42% | $61.99K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 20,350 | 0.31% | $29.51K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 3,969 | 0.06% | $8.93K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 1,551 | 0.02% | $3.49K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Timothy Warbington | President & CEO, Director, 10% owner | 1,047,113 | 15.88% | Sep 25, 2026 |
| Acquisition Corp. Creative | Director | – | – | Sep 25, 2026 |
| Michael H. Finger | Director | 351 | 0.01% | Feb 20, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Timothy Warbington President & CEO, Director, 10% owner | Sep 24, 2026 | Award | +1,000,000 | – | – | 1,034,904 |
| Michael H. Finger Director | Feb 19, 2025 | Sale | −750 | $5.75 | $4.31K | 351 |
| Michael H. Finger Director | Feb 18, 2025 | Sale | −750 | $5.00 | $3.75K | 1,101 |
| Timothy Warbington President & CEO, Director | Jun 28, 2023 | Buy | +200 | $4.36 | $872 | 12,209 |
| Timothy Warbington President & CEO, Director | Jun 27, 2023 | Buy | +300 | $4.45 | $1.34K | 11,809 |
| Timothy Warbington President & CEO, Director | Jun 27, 2023 | Buy | +300 | $4.40 | $1.32K | 11,509 |
| Timothy Warbington President & CEO, Director | Jun 27, 2023 | Buy | +200 | $4.48 | $896 | 12,009 |
| Timothy Warbington President & CEO, Director | Nov 22, 2022 | Buy | +200 | $0.38 | $76 | 112,087 |
| Timothy Warbington President & CEO, Director | Nov 22, 2022 | Buy | +9,800 | $0.39 | $3.82K | 111,887 |
| Timothy Warbington President & CEO, Director | Nov 21, 2022 | Buy | +5,000 | $0.39 | $1.95K | 102,087 |
| Timothy Warbington President & CEO, Director | Nov 21, 2022 | Buy | +10,000 | $0.40 | $4.00K | 97,087 |
| Michael H. Finger Director | Sep 27, 2022 | Buy | +2,000 | $0.50 | $1.00K | 18,502 |
| Timothy Warbington President & CEO, Director | Sep 27, 2022 | Buy | +20,000 | $0.50 | $10.00K | 87,087 |
| Timothy Warbington President & CEO, Director | Sep 22, 2022 | Buy | +12,000 | $0.54 | $6.48K | 67,087 |
| Timothy Warbington President & CEO, Director | Sep 21, 2022 | Buy | +4,500 | $0.64 | $2.88K | 34,587 |
| Timothy Warbington President & CEO, Director | Sep 21, 2022 | Buy | +5,000 | $0.61 | $3.05K | 30,087 |
| Timothy Warbington President & CEO, Director | Sep 21, 2022 | Buy | +20,000 | $0.61 | $12.20K | 55,087 |
| Timothy Warbington President & CEO, Director | Sep 21, 2022 | Buy | +500 | $0.63 | $315 | 35,087 |
| Michael H. Finger Director | Jun 14, 2022 | Buy | +10,000 | $0.70 | $7.00K | 16,502 |
| Timothy Warbington President & CEO, Director | Jun 6, 2022 | Buy | +2,000 | $0.92 | $1.84K | 2,087 |
| Timothy Warbington President & CEO, Director | Jun 6, 2022 | Buy | +8,000 | $0.92 | $7.36K | 10,087 |
| Timothy Warbington President & CEO, Director | Jun 6, 2022 | Buy | +15,000 | $0.91 | $13.65K | 25,087 |
| Michael H. Finger Director | May 20, 2022 | Buy | +6,500 | $1.50 | $9.75K | 6,502 |
| Thomas Ichim Director | Jul 22, 2021 | Sale | −1,450,000 | $0.03 | $43.50K | 4,529,522 |
| Thomas Ichim Director | Jul 21, 2021 | Sale | −1,500,000 | $0.03 | $45.00K | 5,979,522 |
| Thomas Ichim Director | Jul 20, 2021 | Sale | −1,400,000 | $0.03 | $42.00K | 7,479,522 |
| Thomas Ichim Director | Jun 28, 2021 | Option exercise | +10,000,000 | – | – | 10,000,000 |
| Thomas Ichim Director | Jun 28, 2021 | Tax withholding | −1,120,448 | $0.04 | $44.82K | 8,879,552 |
| Medical Health Inc. Creative 10% owner | Jan 8, 2021 | Other | +44,642,857 | – | – | 113,474,233 |
| Timothy Warbington President & CEO, Director, 10% owner | Jan 8, 2021 | Other | +44,642,857 | – | – | 113,474,233 |
| Timothy Warbington President & CEO, Director, 10% owner | Sep 30, 2020 | Other | +42,328,042 | – | – | 68,831,376 |
| Medical Health Inc. Creative 10% owner | Sep 30, 2020 | Other | +42,328,042 | – | – | 68,831,376 |
| Medical Health Inc. Creative 10% owner | Jun 3, 2020 | Other | +19,736,842 | – | – | 26,503,334 |
| Timothy Warbington President & CEO, Director, 10% owner | Jun 3, 2020 | Other | +19,736,842 | – | – | 26,503,334 |
| Timothy Warbington President & CEO, Director, 10% owner | Feb 17, 2020 | Other | +2,250,000 | $0.02 | $45.00K | 6,766,492 |
| Medical Health Inc. Creative 10% owner | Feb 17, 2020 | Other | +2,250,000 | $0.02 | $45.00K | 6,766,492 |
| Timothy Warbington President & CEO, Director, 10% owner | Dec 13, 2019 | Other | +500,000,000 | – | – | 677,473,616 |
| Medical Health Inc. Creative 10% owner | Dec 13, 2019 | Other | +500,000,000 | – | – | 677,473,616 |
| Timothy Warbington President & CEO, Director, 10% owner | Nov 5, 2019 | Other | +100,000,000 | – | – | 177,473,616 |
| Medical Health Inc. Creative 10% owner | Nov 5, 2019 | Other | +100,000,000 | – | – | 177,473,616 |
| Medical Health Inc. Creative 10% owner | Jun 30, 2019 | Other | +10,000,000 | $0.01 | $100.00K | 77,473,616 |
| Timothy Warbington President & CEO, Director, 10% owner | Jun 30, 2019 | Other | +10,000,000 | $0.01 | $100.00K | 77,473,616 |
| Medical Health Inc. Creative 10% owner | Oct 17, 2018 | Conversion | +4,444,444 | $0.02 | $88.89K | 72,955,661 |
| Timothy Warbington President & CEO, Director, 10% owner | Oct 17, 2018 | Conversion | +4,444,444 | $0.02 | $88.89K | 72,955,661 |
| Timothy Warbington President & CEO, Director, 10% owner | Apr 11, 2018 | Conversion | +9,855,290 | $0.01 | $98.55K | 68,511,217 |
| Medical Health Inc. Creative 10% owner | Apr 11, 2018 | Conversion | +9,855,290 | $0.01 | $98.55K | 68,511,217 |
| Timothy Warbington CEO & President, Director, 10% owner | Aug 29, 2017 | Sale | −5,000 | $0.20 | $1.00K | 58,655,927 |
| Medical Health Inc. Creative 10% owner | Aug 29, 2017 | Sale | −5,000 | $0.20 | $1.00K | 58,655,927 |
| Timothy Warbington President & CEO, Director, 10% owner | Jun 5, 2017 | Sale | −2,800 | $0.30 | $840 | 58,605,927 |
| Timothy Warbington President & CEO, Director, 10% owner | Jun 5, 2017 | Sale | −2,500 | $0.31 | $775 | 58,608,727 |
| Medical Health Inc. Creative 10% owner | Jun 5, 2017 | Sale | −2,500 | $0.31 | $775 | 58,608,727 |
| Medical Health Inc. Creative 10% owner | Jun 5, 2017 | Sale | −2,800 | $0.30 | $840 | 58,605,927 |
| Timothy Warbington President & CEO, Director, 10% owner | Jun 2, 2017 | Sale | −2,200 | $0.42 | $924 | 58,611,227 |
| Timothy Warbington President & CEO, Director, 10% owner | Jun 2, 2017 | Sale | −3,500 | $0.40 | $1.40K | 58,613,427 |
| Medical Health Inc. Creative 10% owner | Jun 2, 2017 | Sale | −2,200 | $0.42 | $924 | 58,611,227 |
| Medical Health Inc. Creative 10% owner | Jun 2, 2017 | Sale | −3,500 | $0.40 | $1.40K | 58,613,427 |
| Timothy Warbington President & CEO, Director, 10% owner | May 18, 2017 | Sale | −1,400 | $0.45 | $630 | 58,616,927 |
| Medical Health Inc. Creative 10% owner | May 18, 2017 | Sale | −1,400 | $0.45 | $630 | 58,616,927 |
| Medical Health Inc. Creative 10% owner | Dec 31, 2016 | Sale | −2,935,609 | $0.10 | $293.56K | 58,618,267 |
| Timothy Warbington President & CEO, Director, 10% owner | Dec 31, 2016 | Sale | −2,935,609 | $0.10 | $293.56K | 58,618,267 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
1.19%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-19.4%
From 0M shares
Short volume, 20 days
31.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Creative Medical Technology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 454,563 shares on Sep 22, 2026 over the last 90 days.
See a number that looks wrong?